Topic
Topic
Merck's tulisokibart produced the first positive Phase II efficacy data for an anti-TL1A antibody in a dermatologic indication, opening a new mechanistic category in inflammatory skin disease drug de…
Tulisokibart demonstrated efficacy in a Phase 2b study of patients with moderate to severe hidradenitis suppurativa, HCPLive repo…
Merck's tulisokibart met its primary endpoint in the first Phase II anti-TL1A dermatology trial, per The Pharma Letter — a first-…
Tulisokibart met its primary endpoint in a Phase 2b hidradenitis suppurativa trial, advancing a new anti-TNF candidate toward Pha…
High-dose tulisokibart reached HiSCR50 in 72% of HS patients at week 16 vs 35% on placebo in Merck's phase 2b MK-7240-012 trial,…